• FirefoxInstall the new Firefox »
  •  Dow Down0.06% Nasdaq Up0.42%

    Alexza Pharmaceuticals Inc. (ALXA)

    2.05 Down 0.05(2.38%) Feb 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Alexza Pharmaceuticals Inc.
    2091 Stierlin Court
    Mountain View, CA 94043
    United States - Map
    Phone: 650-944-7000
    Website: http://www.alexza.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:90

    Business Summary 

    Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Its lead product, ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company’s product candidate in development, AZ-002 (Staccato alprazolam), is indicated for the treatment of acute repetitive seizures. It has strategic collaborations with Grupo Ferrer Internacional S.A. and Teva Pharmaceuticals USA, Inc. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alexza Pharmaceuticals Inc.

    Key Executives 
    Mr. Thomas B. King , 60
    Chief Exec. Officer, Pres and Director
    Mr. Mark K. Oki CPA, 46
    Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
    Mr. Robert A. Lippe , 50
    Chief Operations Officer and Exec. VP of Operations
    Dr. Tatjana Naranda Ph.D.,
    VP of Bus. Devel. and Global Alliance Management
    Dr. Edwin S. Kamemoto Ph.D.,
    Sr. VP of Regulatory Affairs
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders